Get the Stockscreener App
806.46
1.20%
-9.76
After Hours:
806.03
-0.43
-0.05%
Argen X Se Adr stock is traded at $806.46, with a volume of 171.18K.
It is down -1.20% in the last 24 hours and up +1.67% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$816.22
Open:
$819.62
24h Volume:
171.18K
Relative Volume:
0.50
Market Cap:
$50.15B
Revenue:
$4.16B
Net Income/Loss:
$1.29B
P/E Ratio:
41.18
EPS:
19.5837
Net Cash Flow:
$734.26M
1W Performance:
+0.89%
1M Performance:
+1.67%
6M Performance:
-12.24%
1Y Performance:
+38.70%
1-Day Range:
$804.20
$827.37
1-Week Range:
$775.62
$827.65
52-Week Range:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
Evercore ISI Raises its Price Target on argenx (ARGX) - Yahoo Finance
Jefferies updates franchise picks list, adding AMZN, APP, MCD and more - MSN
ARGX.BR Stock Price, Quote & Chart | ARGENX SE (EBR:ARGX) - ChartMill
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth By Investing.com - Investing.com Australia
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight - GlobeNewswire Inc.
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth - Investing.com
argenx SE (ARGX) Stock Price, Trades & News - GuruFocus
Argenx SE stock (NL0010832176): FMR LLC boosts stake amid price gains - AD HOC NEWS
Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips - Investing.com
Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy? - Yahoo Finance
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease - Sahm
argenx stock gains after FDA expands MG treatment approval By Investing.com - Investing.com South Africa
argenx stock gains after FDA expands MG treatment approval - Investing.com
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - ChartMill
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Canada
argenx posts 63% revenue growth on strong Vyvgart sales By Investing.com - Investing.com South Africa
Argenx (ARGX) tops earnings expectations despite slight revenue shortfall - Yahoo Finance
argenx appoints Karen Massey as CEO, founder moves to chair - Investing.com
argenx appoints Karen Massey as CEO, founder moves to chair By Investing.com - Investing.com India
argenx to Present at BofA Securities 2026 Health Care Conference - ChartMill
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer - ChartMill
Here’s Why Argenx SE (ARGX) Slipped in Q1 - Yahoo Finance
ARGX.BR Technical Analysis | Trend, Signals & Chart Patterns | ARGENX SE (EBR:ARGX) - ChartMill
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 - ChartMill
ARGX Stock Price, Quote & Chart | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Regeneron (REGN) - The Globe and Mail
argenx SE Stock Baskets | MEX:ARGXN - GuruFocus
argenx SE Stock Operating Data - GuruFocus
argenx SE (MEX:ARGXN) Stock News, Headlines & Updates - GuruFocus
US-Listed European ADRs Slipped As Drugmakers Weighed On The Tape - Finimize
Argenx SE stock (NL0010832176): Is its rare disease focus strong enough to unlock sustained U.S. gro - AD HOC NEWS
The Bull Case For argenx (ENXTBR:ARGX) Could Change Following New VYVGART Ocular MG Efficacy Data - Yahoo Finance
Argenx SE stock (NL0010832176): Is Vyvgart's momentum strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's expansion strong enough to unlock new upside? - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's rare disease dominance strong enough to unlock new upsi - AD HOC NEWS
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. momentum strong enough to unlock new upside? - AD HOC NEWS
argenx SE (MEX:ARGXN) Competitors 2026 - GuruFocus
Who's Buying or Selling argenx SE (MEX:ARGXN) Stock Today? - GuruFocus
argenx SE (MEX:ARGXN) Stock Price, Trades & News - GuruFocus
argenx SE (MEX:ARGXN)Valuation Measures & Financial Statistics - GuruFocus
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP - ChartMill
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Avalo Therapeutics (AVTX) - The Globe and Mail
Argenx SE stock (NL0010832176): Is Vyvgart's U.S. expansion strong enough to unlock new upside? - AD HOC NEWS
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):